Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome
Purpose To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT). Study design An institutional review board-approved single-center not randomized prospective study. Methods Fif...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of ophthalmology Jg. 63; H. 3; S. 255 - 261 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Tokyo
Springer Japan
01.05.2019
Springer Nature B.V |
| Schlagworte: | |
| ISSN: | 0021-5155, 1613-2246, 1613-2246 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Purpose
To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT).
Study design
An institutional review board-approved single-center not randomized prospective study.
Methods
Fifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT.
Results
The mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT.
Conclusion
Our study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients. |
|---|---|
| AbstractList | To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT).PURPOSETo evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT).An institutional review board-approved single-center not randomized prospective study.STUDY DESIGNAn institutional review board-approved single-center not randomized prospective study.Fifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT.METHODSFifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT.The mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT.RESULTSThe mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT.Our study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients.CONCLUSIONOur study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients. Purpose To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT). Study design An institutional review board-approved single-center not randomized prospective study. Methods Fifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT. Results The mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT. Conclusion Our study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients. PurposeTo evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT).Study designAn institutional review board-approved single-center not randomized prospective study.MethodsFifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT.ResultsThe mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT.ConclusionOur study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients. To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT). An institutional review board-approved single-center not randomized prospective study. Fifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT. The mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT. Our study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients. |
| Author | Cavallero, Edoardo Pirani, Vittorio Mariotti, Cesare Pelliccioni, Paolo Carrozzi, Giulia Cesari, Claudia |
| Author_xml | – sequence: 1 givenname: Vittorio surname: Pirani fullname: Pirani, Vittorio organization: Eye Clinic, Polytechnic University of Marche, Eye Clinic, University Hospital “Ospedali Riuniti” – sequence: 2 givenname: Paolo orcidid: 0000-0002-6024-0183 surname: Pelliccioni fullname: Pelliccioni, Paolo email: paopel@hotmail.it organization: Eye Clinic, Polytechnic University of Marche, Eye Clinic, University Hospital “Ospedali Riuniti” – sequence: 3 givenname: Claudia surname: Cesari fullname: Cesari, Claudia organization: Eye Clinic, Polytechnic University of Marche, Eye Clinic, University Hospital “Ospedali Riuniti” – sequence: 4 givenname: Giulia surname: Carrozzi fullname: Carrozzi, Giulia organization: Eye Clinic, Polytechnic University of Marche, Eye Clinic, University Hospital “Ospedali Riuniti” – sequence: 5 givenname: Edoardo surname: Cavallero fullname: Cavallero, Edoardo organization: Eye Clinic, Polytechnic University of Marche, Eye Clinic, University Hospital “Ospedali Riuniti” – sequence: 6 givenname: Cesare surname: Mariotti fullname: Mariotti, Cesare organization: Eye Clinic, Polytechnic University of Marche, Eye Clinic, University Hospital “Ospedali Riuniti” |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30805734$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9PGzEQxa0KVALtF-BQrdRLL0vHf9Z2jgiVgoTEpZwtx-uAo1072N5K4dN3woIqcYh8sEf-vaeZeafkKKboCTmncEEB1M9CgWvRAl22AFJC-_KJLKikvGVMyCOyAGC07WjXnZDTUjYAIBhnn8kJBw2d4mJBnq4Hm33jnmx89KWx6-pzE2LN9m-o2dsBi413NaTYpHWTXA7bwZYxRPxoym7c1jTaGlzzyuPbTejYoMEsKrvY5zT6L-R4bYfiv77dZ-Th-tefq5v27v737dXlXesEU7VdgRXAernS1nKxdApWOCNTlqpe8J5xwZ3ntu-soJ12SlCqtd8PBpJ3nPEz8mP23eb0PPlSzRiK88Ngo09TMYxqSQWVbIno9w_oJk05YneGMyk55YDnAIVenVoqrTVS396oaTX63mxzGG3emfdNI6BnwOVUSvZr40K1-xXhqsJgKJh9qGYO1WCo5jVU84JS9kH67n5QxGdRQRizzf_bPqD6B9lWs7A |
| CitedBy_id | crossref_primary_10_1177_11206721221137169 crossref_primary_10_1186_s40942_023_00472_x crossref_primary_10_1177_11206721221099251 crossref_primary_10_3389_fmolb_2023_1169718 crossref_primary_10_3389_fgene_2022_994163 |
| Cites_doi | 10.1016/j.ajo.2012.10.016 10.1016/j.ophtha.2014.07.044 10.1097/IAE.0000000000000519 10.1007/s00417-015-3031-1 10.1167/iovs.04-1517 10.1080/14786446908640137 10.1080/08820538.2016.1228416 10.1097/IAE.0b013e31829232fd 10.1097/IAE.0b013e3180654229 10.1097/IAE.0000000000000334 10.3109/09273948.2015.1108445 10.3928/23258160-20160126-09 10.1016/0002-9394(70)91041-X 10.1016/j.ophtha.2013.07.042 10.1159/000446842 10.1007/s00417-018-4141-3 10.1007/s10792-009-9310-2 10.3928/1542-8877-19980501-05 |
| ContentType | Journal Article |
| Copyright | Japanese Ophthalmological Society 2019 Japanese Journal of Ophthalmology is a copyright of Springer, (2019). All Rights Reserved. Japanese Ophthalmological Society 2019. |
| Copyright_xml | – notice: Japanese Ophthalmological Society 2019 – notice: Japanese Journal of Ophthalmology is a copyright of Springer, (2019). All Rights Reserved. – notice: Japanese Ophthalmological Society 2019. |
| DBID | AAYXX CITATION NPM 3V. 7QL 7T7 7U9 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FR3 FYUFA GHDGH H94 K9. M0S M1P M7N P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s10384-019-00660-z |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Technology Research Database Technology Research Database PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1613-2246 |
| EndPage | 261 |
| ExternalDocumentID | 30805734 10_1007_s10384_019_00660_z |
| Genre | Journal Article |
| GroupedDBID | --- -5E -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29J 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 3V. 4.4 406 408 409 40D 40E 5GY 5VS 67Z 6NX 7X7 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACNCT ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FDB FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HLICF HMJXF HQYDN HRMNR HVGLF HZ~ I09 IJ- IKXTQ ITM IWAJR IXC IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LLZTM M4Y MA- NB0 NPVJJ NQJWS NU0 O93 O9I O9J OAM P2P P9S PF0 PROAC PT4 Q2X QOR QOS R89 R9I ROL RPX RRX RSV S16 S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z87 ZMTXR ZOVNA ~A9 --K -Y2 .55 .GJ 1B1 1~5 2P1 2VQ 3O- 4G. 53G 7-5 88E 8AO 8FI 8FJ 9DU AAEDT AALRI AANXM AAPKM AAQFI AAQXK AARHV AAXUO AAYXX ABBRH ABDBE ABFSG ABQSL ABRTQ ABULA ABUWG ABWVN ACIUM ACRPL ACSTC ADHKG ADMUD ADNMO ADPHR AEBTG AEKMD AEUPX AEZWR AFDZB AFFHD AFHIU AFKRA AFOHR AFPUW AGQPQ AHPBZ AHSBF AHWEU AIXLP AJBLW ATHPR BVXVI CAG CCPQU CITATION COF EN4 FGOYB H13 HMCUK IHE M1P M41 N2Q NQ- O9- PHGZM PHGZT PJZUB PPXIY PQQKQ PSQYO R2- RPZ S1Z SEW SSZ TKC UKHRP X7J X7M ZGI NPM 7QL 7T7 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N P64 PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c427t-b0a402d6b8aa349c70b38427a17d43d2343ce3ad5a4158c741188e00420635323 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000466341000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0021-5155 1613-2246 |
| IngestDate | Sun Sep 28 16:11:47 EDT 2025 Thu Oct 30 03:55:16 EDT 2025 Fri Oct 03 09:52:11 EDT 2025 Thu Apr 03 07:07:40 EDT 2025 Sat Nov 29 06:05:17 EST 2025 Tue Nov 18 21:49:59 EST 2025 Fri Feb 21 02:35:03 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Ocriplasmin Vitreomacular traction syndrome Laser flare photometry Intravitreal injection |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c427t-b0a402d6b8aa349c70b38427a17d43d2343ce3ad5a4158c741188e00420635323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-6024-0183 |
| PMID | 30805734 |
| PQID | 2185797888 |
| PQPubID | 34516 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2186141629 proquest_journals_3266313030 proquest_journals_2185797888 pubmed_primary_30805734 crossref_citationtrail_10_1007_s10384_019_00660_z crossref_primary_10_1007_s10384_019_00660_z springer_journals_10_1007_s10384_019_00660_z |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-01 |
| PublicationDateYYYYMMDD | 2019-05-01 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Japan |
| PublicationSubtitle | The Official International Journal of the Japanese Ophthalmological Society |
| PublicationTitle | Japanese journal of ophthalmology |
| PublicationTitleAbbrev | Jpn J Ophthalmol |
| PublicationTitleAlternate | Jpn J Ophthalmol |
| PublicationYear | 2019 |
| Publisher | Springer Japan Springer Nature B.V |
| Publisher_xml | – name: Springer Japan – name: Springer Nature B.V |
| References | Johnson (CR3) 2013; 155 Hahn, Chung, Flynn, Huang, Kim, Mahmoud (CR5) 2015; 35 Sakuma, Tanaka, Mizota, Inoue, Pakola (CR19) 2015; 46 Reese, Jones, Cooper (CR1) 1970; 69 el-Harazi, Feldman, Chuang, Ruiz, Villanueva (CR11) 1998; 29 Itoh, Kaiser, Singh, Srivastava, Ehlers (CR18) 2014; 121 Duker, Kaiser, Binder, de Smet, Gaudric, Reichel (CR4) 2013; 120 Figueira, Martins, Pessoa, Ferreira, Meireles, Sampaio (CR7) 2016; 56 Tugal-Tutkun, Herbort (CR12) 2010; 30 Morioka, Takamura, Yamada, Matsumura, Gozawa, Inatani (CR15) 2018; 256 Uzun, Yalcindag, Demirel, Batýoðlu, Ozmert (CR14) 2017; 25 Sawa, Tsurimaki, Tsuru, Shimizu (CR9) 1988; 32 Shah, Jeng-Miller, Fine, Wheatley, Roth, Prenner (CR6) 2016; 47 Jackson, Nicod, Simpson, Angelis, Grimaccia, Kanavos (CR2) 2013; 33 Quiram, Leverenz, Baker, Dang, Giblin, Trese (CR16) 2007; 27 Shaikh, Miller, Papakostas, Husain (CR17) 2017; 32 Chatziralli, Theodossiadis, Parikakis, Datseris, Theodossiadis (CR20) 2016; 254 Shah, Spalton, Taylor (CR10) 1992; 33 Tyndall (CR8) 1869; 37 Blaha, Brooks, Mackel, Pani, Stewart, Price (CR13) 2015; 35 G Blaha (660_CR13) 2015; 35 SP Shah (660_CR6) 2016; 47 A Uzun (660_CR14) 2017; 25 I Chatziralli (660_CR20) 2016; 254 AB Reese (660_CR1) 1970; 69 MW Johnson (660_CR3) 2013; 155 Y Itoh (660_CR18) 2014; 121 JS Duker (660_CR4) 2013; 120 J Figueira (660_CR7) 2016; 56 SM Shah (660_CR10) 1992; 33 J Tyndall (660_CR8) 1869; 37 M Morioka (660_CR15) 2018; 256 TL Jackson (660_CR2) 2013; 33 I Tugal-Tutkun (660_CR12) 2010; 30 P Quiram (660_CR16) 2007; 27 M Sawa (660_CR9) 1988; 32 SM el-Harazi (660_CR11) 1998; 29 P Hahn (660_CR5) 2015; 35 M Shaikh (660_CR17) 2017; 32 T Sakuma (660_CR19) 2015; 46 |
| References_xml | – volume: 155 start-page: 203–205.e1 year: 2013 ident: CR3 article-title: How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically? publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2012.10.016 – volume: 121 start-page: 2506–7.e2 year: 2014 ident: CR18 article-title: Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.07.044 – volume: 35 start-page: 1128 year: 2015 end-page: 1134 ident: CR5 article-title: Safety profile of ocriplasmin for symptomatic vitreomacular adhesion: a comprehensive analysis of premarketing and postmarketing experiences publication-title: Retina doi: 10.1097/IAE.0000000000000519 – volume: 254 start-page: 223 year: 2016 end-page: 233 ident: CR20 article-title: Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: A spectral-domain optical coherence tomography prospective study publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-015-3031-1 – volume: 46 start-page: 3295 year: 2015 end-page: 3299 ident: CR19 article-title: Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes publication-title: Investig Ophthalmol Vis Sci doi: 10.1167/iovs.04-1517 – volume: 33 start-page: 2878 year: 1992 end-page: 2884 ident: CR10 article-title: Correlations between laser flare measurements and anterior chamber protein concentrations publication-title: Investig Ophthalmol Vis Sci – volume: 32 start-page: 132 year: 1988 end-page: 142 ident: CR9 article-title: New quantitative method to determine protein concentration and cell number in aqueous in vivo publication-title: Jpn J Ophthalmol – volume: 37 start-page: 384 year: 1869 end-page: 404 ident: CR8 article-title: On the blue of the sky, the polarization of the skylight, and on the polarization of light by cloudy matter generally publication-title: Philos Mag J Sci doi: 10.1080/14786446908640137 – volume: 32 start-page: 52 year: 2017 end-page: 55 ident: CR17 article-title: The efficacy and safety profile of ocriplasmin in vitreomacular interface disorders publication-title: Semin Ophthalmol doi: 10.1080/08820538.2016.1228416 – volume: 33 start-page: 1503 year: 2013 end-page: 1511 ident: CR2 article-title: Symptomatic vitreomacular adhesion publication-title: Retina doi: 10.1097/IAE.0b013e31829232fd – volume: 27 start-page: 1090 year: 2007 end-page: 1096 ident: CR16 article-title: Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels publication-title: Retina doi: 10.1097/IAE.0b013e3180654229 – volume: 35 start-page: 577 year: 2015 end-page: 581 ident: CR13 article-title: Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications publication-title: Retina doi: 10.1097/IAE.0000000000000334 – volume: 25 start-page: 229 year: 2017 end-page: 232 ident: CR14 article-title: Evaluation of aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration publication-title: Ocul Immunol Inflamm doi: 10.3109/09273948.2015.1108445 – volume: 47 start-page: 156 year: 2016 end-page: 160 ident: CR6 article-title: Post-marketing survey of adverse events following ocriplasmin publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20160126-09 – volume: 69 start-page: 975 year: 1970 end-page: 977 ident: CR1 article-title: Vitreomacular traction syndrome confirmed histologically publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(70)91041-X – volume: 120 start-page: 2611 year: 2013 end-page: 2619 ident: CR4 article-title: The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.07.042 – volume: 56 start-page: 186 issue: 4 year: 2016 end-page: 192 ident: CR7 article-title: The Portuguese experience with ocriplasmin in clinical practice publication-title: Ophthalmic Res doi: 10.1159/000446842 – volume: 29 start-page: 380 year: 1998 end-page: 384 ident: CR11 article-title: Reproducibility of the laser flare meter and laser cell counter in assessing anterior chamber inflammation following cataract surgery publication-title: Ophthalmic Surg Lasers – volume: 256 start-page: 2301 year: 2018 end-page: 2307 ident: CR15 article-title: Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-018-4141-3 – volume: 30 start-page: 453 year: 2010 end-page: 464 ident: CR12 article-title: Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation publication-title: Int Ophthalmol doi: 10.1007/s10792-009-9310-2 – volume: 256 start-page: 2301 year: 2018 ident: 660_CR15 publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-018-4141-3 – volume: 32 start-page: 52 year: 2017 ident: 660_CR17 publication-title: Semin Ophthalmol doi: 10.1080/08820538.2016.1228416 – volume: 35 start-page: 1128 year: 2015 ident: 660_CR5 publication-title: Retina doi: 10.1097/IAE.0000000000000519 – volume: 155 start-page: 203–205.e1 year: 2013 ident: 660_CR3 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2012.10.016 – volume: 29 start-page: 380 year: 1998 ident: 660_CR11 publication-title: Ophthalmic Surg Lasers doi: 10.3928/1542-8877-19980501-05 – volume: 254 start-page: 223 year: 2016 ident: 660_CR20 publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-015-3031-1 – volume: 30 start-page: 453 year: 2010 ident: 660_CR12 publication-title: Int Ophthalmol doi: 10.1007/s10792-009-9310-2 – volume: 56 start-page: 186 issue: 4 year: 2016 ident: 660_CR7 publication-title: Ophthalmic Res doi: 10.1159/000446842 – volume: 121 start-page: 2506–7.e2 year: 2014 ident: 660_CR18 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.07.044 – volume: 33 start-page: 1503 year: 2013 ident: 660_CR2 publication-title: Retina doi: 10.1097/IAE.0b013e31829232fd – volume: 37 start-page: 384 year: 1869 ident: 660_CR8 publication-title: Philos Mag J Sci doi: 10.1080/14786446908640137 – volume: 46 start-page: 3295 year: 2015 ident: 660_CR19 publication-title: Investig Ophthalmol Vis Sci doi: 10.1167/iovs.04-1517 – volume: 33 start-page: 2878 year: 1992 ident: 660_CR10 publication-title: Investig Ophthalmol Vis Sci – volume: 47 start-page: 156 year: 2016 ident: 660_CR6 publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20160126-09 – volume: 120 start-page: 2611 year: 2013 ident: 660_CR4 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.07.042 – volume: 35 start-page: 577 year: 2015 ident: 660_CR13 publication-title: Retina doi: 10.1097/IAE.0000000000000334 – volume: 27 start-page: 1090 year: 2007 ident: 660_CR16 publication-title: Retina doi: 10.1097/IAE.0b013e3180654229 – volume: 69 start-page: 975 year: 1970 ident: 660_CR1 publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(70)91041-X – volume: 32 start-page: 132 year: 1988 ident: 660_CR9 publication-title: Jpn J Ophthalmol – volume: 25 start-page: 229 year: 2017 ident: 660_CR14 publication-title: Ocul Immunol Inflamm doi: 10.3109/09273948.2015.1108445 |
| SSID | ssj0004232 |
| Score | 2.2155116 |
| Snippet | Purpose
To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic... To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular... PurposeTo evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic... To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 255 |
| SubjectTerms | Anterior chamber Chambers Clinical Investigation Diabetes Edema Injection Iodine Lasers Measurement techniques Medicine Medicine & Public Health Ophthalmology Patients Photons Statistical analysis Tomography Traction Women |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4VWlW9QGlpSUuRK3EDS4ntXdtHVHXVS1FVHuIWee2sWLQkaBOQyq9nxkl2i6BI5ZbIjuVMZjzfZF4Au_RrI_PS82AmKVeFtXxsQsqtc94GJ0LQITab0IeH5uzM_uqSwuo-2r13ScaT-q9kN2koYsJy0pMpv12Bl6juDInj76PTZTakkF2N8IxTA5MuVebxNe6rowcY84F_NKqd0frzNvwW1jqYyQ5avtiAF0X5Dl7_7Bzp7-F8hBZtwdq035rFTuFsSj96b6YUez7Dm4sYpVWyasIqOlsQZ19OSxxg9Z_Lq6aKxV5ZnI_XMZ6VNfM2UYL1lRA24WT0_fjbD941XeBeCd3wcerQpAzDsXFOKut1Osa3ENplOigZhFTSF9KFgUPVbzwCksyYgqiOYGcghfwAq2VVFlvAsoDwyJOnR2llht5aHSZ4hiht0dA0IYGsp33uu4rk1Bhjli9rKRMJcyRhHkmY3yawt3jmqq3H8eTs7f6T5p1s1rmg8leWTP9HhxHPDiVp9jSBr4thFDrypLiyqK7jEghrsqGwCXxsOWWxG4kYfKClSmC_Z4vl4v_e6qf_m_4Z3ojIWRR6uQ2rzfy6-AKv_E0zrec7USDuANVdA_4 priority: 102 providerName: Springer Nature |
| Title | Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome |
| URI | https://link.springer.com/article/10.1007/s10384-019-00660-z https://www.ncbi.nlm.nih.gov/pubmed/30805734 https://www.proquest.com/docview/2185797888 https://www.proquest.com/docview/3266313030 https://www.proquest.com/docview/2186141629 |
| Volume | 63 |
| WOSCitedRecordID | wos000466341000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1613-2246 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0004232 issn: 0021-5155 databaseCode: 7X7 dateStart: 20040101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1613-2246 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0004232 issn: 0021-5155 databaseCode: BENPR dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1613-2246 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004232 issn: 0021-5155 databaseCode: RSV dateStart: 20040101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFH9iHUJcGN_LNiYjcQOLJHZr-4QAreJCNY0P9Ra5dqoVbUnXZJPYX7_3HKcVGuzCJYplJ3rys59_fp8Ab0i1kTnhuNfzlMvSGD7TPuXGWme8zb1XPhSbUJOJnk7NcVS4NdGtspeJQVD72pGO_D3CjJEggZt-WF5wqhpF1tVYQmMLtilTmRzA9qejyfHJJjIyFzFfeMapmEkMm4nBc0KTB4bhdO6m_PrPo-kW3rxlKw1H0Hjnf4l_DI8i-GQfu9XyBO6V1VN48DWa15_B6RjvuSXrgoEbFuqHswWpf68W5JF-ho1fwXerYvWc1SRxEH2fLyrsYM3v82VbhxSwLIzH9-DlytpVFz7B-vwIz-HH-Oj75y88lmLgTuaq5bPU4kXTj2baWiGNU-kMJy9XNlNeCp8LKVwprB9aBATaIUzJtC5p_hECDUUuXsCgqqtyF1jmETQ5sv9IJfXIGaP8HCWLVAavn9onkPVcKFzMU07lMs6KTYZl4lyBnCsC54rrBN6uv1l2WTruHH3Qc6mIO7YpckqKZUgh8NfuDQcTeL3uxq1I9hVblfVl-AWCnWyUmwRedmtmTY1AZD5UQibwrl9Em5__m9S9u2nZh4d5WMDkgHkAg3Z1Wb6C--6qXTSrQ9hSUxWe-jBuDGydfPt5Axx7EUQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBUEvlHdDCxgJTmA1ibNr-1AhBKxatV1xKNLegtf2ikVtsmzSovZH8Rs74yS7QoXeeuCWyE7iJJ-_mbHnAfCaljYSKyx3ahLzzGvNx8rFXBtjtTOpc9KFYhNyOFSjkf6yAr-7WBhyq-w4MRC1Ky2tkW-jmtEXRLjx-9lPTlWjaHe1K6HRwGLfn_9Ck63a2fuE__dNmg4-H33c5W1VAW6zVNZ8HBu0mVx_rIwRmbYyHguFLSaRLhMuFZmwXhjXMyjblEWJmyjlCdwozXuCEh0g5d9CHpfkQiZHchmHmYo2O3nCqXRKG6TThurhU9Bw15ykfMwv_hSEV7TbKzuzQeAN1v-3T3Uf7rWqNfvQzIUHsOKLh3DnsHUeeATfB2jFe9aEOlcsVEdnU1rcPpuSv_0xnvwInmkFKyesJD5F2-JkWmADq85PZnUZEtyy0B-Pgw8vq-dNcAjrsj88hq838p5PYLUoC78BLHGoElra3cpkpvpWa-kmyJuZ1GhcKxdB0v313LZZ2KkYyHG-zB9NSMkRKXlASn4RwdvFNbMmB8m1vbc6VOQtH1V5Sim_NC13_LV5iZgIXi2akWho98gUvjwNt0BVLumnOoKnDUYXoxFod_SkyCJ414F2efN_D_XZ9WN5CXd3jw4P8oO94f4mrKVh8pCr6Ras1vNT_xxu27N6Ws1fhGnI4NtNg_kSSYRlxA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED8xNiFextgHZLDhSXvbLBLbre1HBFRM2yqkfYi3yLVTrQiSqg1I46_fnZO0TLBJ094S2bEc-2z_znf3O4C3dLWReel5MOOUq8JaPjIh5dY5b4MTIegQk03o4dCcndnTW1H80du9M0k2MQ3E0lTW-9Mw3r8V-CYNeU9YTmdmym8ewENFSYNIX__yfRkZKWTLF55xSmbShs3c38bvR9MdvHnHVhqPoMHG_3f-CTxu4Sc7aORlE1aK8imsfW4N7M_gxwA13YI14cBzFjOIswldAF9PyCf9Al_Oo_dWyaoxq2jPQfx9OSmxgM1_Xk7rKpLAslgfn6OfK6tnTQAF6xgSnsO3wfHXwxPeJmPgXgld81HqUNUM_ZFxTirrdTrCvxDaZTooGYRU0hfShZ5DSGA8ApXMmIJmAEFQTwr5AlbLqiy2gWUBYZMnC5DSyvS9tTqMcW9R2qICakICWTcPuW-ZyilhxkW-5FimIcxxCPM4hPlNAu8W30wbno6_1t7tpjdv1-w8F0SLZelK4N5ixLl9SSd-msCbRTEuRrKwuLKormITCHeyvrAJbDVSs-iNRGze01Il8L4TkWXjf-7qy3-rvgdrp0eD_NOH4ccdWBdRyMg7cxdW69lV8Qoe-et6Mp-9juvkF5m-D8Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Flare+changes+after+intravitreal+injection+of+ocriplasmin+in+symptomatic+vitreomacular+traction+syndrome&rft.jtitle=Japanese+journal+of+ophthalmology&rft.au=Pirani%2C+Vittorio&rft.au=Pelliccioni%2C+Paolo&rft.au=Cesari%2C+Claudia&rft.au=Carrozzi%2C+Giulia&rft.date=2019-05-01&rft.issn=1613-2246&rft.eissn=1613-2246&rft.volume=63&rft.issue=3&rft.spage=255&rft_id=info:doi/10.1007%2Fs10384-019-00660-z&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5155&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5155&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5155&client=summon |